ArticleESC heart failure2024

Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design.

Jaclyn Carberry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.